Stay updated on Cabozantinib Pembrolizumab Combo in Advanced Melanoma Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib Pembrolizumab Combo in Advanced Melanoma Clinical Trial page.

Latest updates to the Cabozantinib Pembrolizumab Combo in Advanced Melanoma Clinical Trial page
- Check7 days agoChange DetectedThe page now shows a glossary, adds a 'Last Update Submitted that Met QC Criteria' field, a 'No FEAR Act Data' indicator, and a 'Revision: v3.4.0' note. The previous 'Last Update Submitted that met QC Criteria' field, FEAR Act wording, and the older 'Revision: v3.3.4' version have been removed.SummaryDifference0.2%

- Check14 days agoChange DetectedThe label 'Last Update Posted (Estimated)' was changed to 'Last Update Posted'.SummaryDifference0.1%

- Check21 days agoChange DetectedThe page revision label changed from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check43 days agoChange DetectedAdded a Locations section with the Iowa site details. Removed the Iowa Locations block and the HHS Vulnerability Disclosure link, and updated the page revision to v3.3.3.SummaryDifference0.2%

- Check72 days agoChange DetectedRevision history updated: added Revision: v3.3.2 and removed Revision: v3.2.0.SummaryDifference0.1%

- Check79 days agoChange DetectedRemoved the government funding lapse notice banner that warned users about possible delays and operating status changes. The banner previously conveyed site-wide operational information.SummaryDifference0.4%

Stay in the know with updates to Cabozantinib Pembrolizumab Combo in Advanced Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib Pembrolizumab Combo in Advanced Melanoma Clinical Trial page.